These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33238212)

  • 1. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.
    Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ
    J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
    Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR
    MAbs; 2010; 2(4):379-94. PubMed ID: 20458189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.
    Ayoub D; Jabs W; Resemann A; Evers W; Evans C; Main L; Baessmann C; Wagner-Rousset E; Suckau D; Beck A
    MAbs; 2013; 5(5):699-710. PubMed ID: 23924801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment.
    Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A
    J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars.
    Millán-Martín S; Jakes C; Carillo S; Bones J
    J Pharm Biomed Anal; 2023 Sep; 234():115543. PubMed ID: 37385093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
    MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
    Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
    J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparability study of Rituximab originator and follow-on biopharmaceutical.
    Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
    J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of the use of sliding window deconvolution for comprehensive characterisation of trastuzumab and adalimumab charge variants by native high resolution mass spectrometry.
    Millán-Martín S; Carillo S; Füssl F; Sutton J; Gazis P; Cook K; Scheffler K; Bones J
    Eur J Pharm Biopharm; 2021 Jan; 158():83-95. PubMed ID: 33212184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel filter-assisted protein precipitation (FAPP) based sample pre-treatment method for LC-MS peptide mapping for biosimilar characterization.
    Bhattacharya S; Rathore AS
    J Pharm Biomed Anal; 2023 Sep; 234():115527. PubMed ID: 37364451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
    J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes.
    Gomes RA; Almeida C; Correia C; Guerreiro A; Simplício AL; Abreu IA; Alves PG
    PLoS One; 2019; 14(7):e0219156. PubMed ID: 31291294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
    Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
    Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Method Development and Qualification of pH-Based CEX UPLC Method for Monoclonal Antibodies.
    Bhatt M; Alok A; Kulkarni BB
    BioTech (Basel); 2022 Jun; 11(2):. PubMed ID: 35822792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid method for relative quantification of
    Segu Z; Stone T; Berdugo C; Roberts A; Doud E; Li Y
    MAbs; 2020; 12(1):1750794. PubMed ID: 32249667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microfluidic capillary electrophoresis - mass spectrometry for rapid charge-variant and glycoform assessment of monoclonal antibody biosimilar candidates.
    Cageling R; Carillo S; Boumeester AJ; Lubbers-Geuijen K; Bones J; Jooß K; Somsen GW
    J Pharm Biomed Anal; 2024 Sep; 248():116301. PubMed ID: 38901155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.